Atrial Fibrillation

Atrial Fibrillation Guidelines App

ACC/AHA Atrial Fibrillation GUIDELINES Apps brought to you charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387805

Contents of this Issue

Navigation

Page 27 of 31

Treatment 26 Table 22. WPW and Pre-Excitation Syndromes Recommendations COR LOE Prompt direct-current cardioversion is recommended for patients with AF, WPW, and RVR who are hemodynamically compromised. I C Intravenous procainamide or ibutilide to restore sinus rhythm or slow the ventricular rate is recommended for patients with pre-excited AF and RVR who are not hemodynamically compromised. I C Catheter ablation of the accessory pathway is recommended in symptomatic patients with pre-excited AF, especially if the accessory pathway has a short refractory period that allows rapid antegrade conduction. I C Administration of intravenous amiodarone, adenosine, digoxin (oral or intravenous), or nondihydropyridine calcium channel antagonists (oral or intravenous) in patients with WPW syndrome who have pre-excited AF is potentially harmful because these drugs accelerate the ventricular rate. III: Harm B Table 23. Heart Failure Recommendations COR LOE Control of resting heart rate using either a beta blocker or a nondihydropyridine calcium channel antagonist is recommended for patients with persistent or permanent AF and compensated HFpEF. I B In the absence of pre-excitation, intravenous beta-blocker administration (or a nondihydropyridine calcium channel antagonist in patients with HFpEF) is recommended to slow the ventricular response to AF in the acute setting, with caution needed in patients with overt congestion, hypotension, or HF with reduced LVEF. I B In the absence of pre-excitation, intravenous digoxin or amiodarone is recommended to control heart rate acutely in patients with HF. I B Table 21. Pulmonary Disease Recommendations COR LOE A nondihydropyridine calcium channel antagonist is recommended to control the ventricular rate in patients with AF and chronic obstructive pulmonary disease. I C Direct-current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable as a consequence of new onset AF. I C

Articles in this issue

Archives of this issue

view archives of Atrial Fibrillation - Atrial Fibrillation Guidelines App